Advertisement
Product › Details
Cerestat®
Next higher product group | Aptiganel | |
Status | 1995-01-01 development existent | |
Organisation | Cambridge NeuroScience Inc. | |
Today | Paion (Group) | |
Group | Humanwell Healthcare (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for pharmaceutical_oo
- [1] Idorsia Ltd.. (3/18/24). "Press Release: Idorsia and Viatris Successfully Close the Transaction for the Global Research and Development Collaboration". Allschwil....
- [2] Idorsia Ltd.. (2/28/24). "Press Release: Idorsia and Viatris Enter into a Significant Global Research and Development Collaboration". Allschwil....
- [3] Santhera Pharmaceuticals Holding AG. (10/27/23). "Press Release: Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy [Ad hoc announcement pursuant to Art. 53 LR]". Pratteln....
- [4] Biogen Inc.. (7/28/23). "Press Release: Biogen to Acquire Reata Pharmaceuticals". Cambridge, MA & Plano, TX....
- [5] Santhera Pharmaceuticals Holding AG. (6/20/23). "Press Release: Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties [Ad hoc announcement pursuant to Art. 53 LR]...
- [6] Ipsen S.A.. (1/9/23). "Press Release: Ipsen to Acquire Albireo Accelerating Growth in Rare Disease with Treatments for Several Pediatric Liver Diseases". Paris & Boston, MA....
- [7] Chiesi Farmaceutici S.p.A.. (1/8/23). "Press Release: Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc". Parma, Boston, MA & Dublin....
- [8] Apogee Therapeutics, LLC. (12/7/22). "Press Release: Apogee Therapeutics Launches with $169 Million to Develop Potentially Best-in-Class Therapies for Immunological and Inflammatory Disorders". San Francisco, CA....
- [9] ObsEva S.A.. (11/22/22). "Press Release: ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million". Geneva....
- [10] Genfit S.A.. (9/19/22). "Press Release: Genfit to Acquire Clinical-stage Biopharmaceutical Company Versantis, Expanding Its Portfolio in Liver Diseases". Lille & Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top